SCHEMBL2192991

SCHEMBL2192991

N#Cc1ccc(OCCC2CCCCC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.54
HSD11B2 P80365 1/20 0.48
NFE2L2 Q16236 1/20 0.47
IDO1 P14902 3/20 0.41
MCHR1 Q99705 1/20 0.40
CHRM4 P08173 1/20 0.40
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
HPGD P15428 1/20 0.38
CTSS P25774 2/20 0.38
CTSL P07711 1/20 0.38
CTSK P43235 1/20 0.38
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
GABRA5 P31644 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195452 0.79 NFE2L2 (0.46) NFE2L2IDO1MCHR1HPGDCTSS
SCHEMBL1625928 0.78 HSD11B1 (0.44) HSD11B1HSD11B2CTSSCTSLCTSK
SCHEMBL29705644 0.78 NFE2L2 (0.39) HSD11B1HSD11B2NFE2L2IDO1MCHR1
SCHEMBL18721894 0.77 HSD11B1 (0.42) HSD11B1HSD11B2NFE2L2CHRM4CTSS
SCHEMBL2585221 0.76 DPP4 (0.52) HSD11B1HSD11B2ALOX5APFEN1DPP4
SCHEMBL31753279 0.76 GPR119 (0.51)
SCHEMBL2195636 0.75 HPGD (0.47) NFE2L2IDO1MCHR1HPGD
SCHEMBL23163700 0.75 NFE2L2 (0.39) HSD11B1HSD11B2NFE2L2IDO1MCHR1
SCHEMBL2695269 0.74 DPP4 (0.53) HSD11B1HSD11B2ALOX5APFEN1DPP4
SCHEMBL23163619 0.74 NFE2L2 (0.36) HSD11B1HSD11B2NFE2L2IDO1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed
EP-2065369-A1 UREA COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF FAAH, FAAH2, UTS2R HSD11B1 1376/4885HSD11B2 1452/4885NFE2L2 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.